Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine

Journal of Internal Medicine

Volumn 271, Issue 2, 2012, Pages 193-203

  Chao, C ^a   Klein, N P ^a   Velicer, C M ^b   Sy, L S ^a   Slezak, J M ^a   Takhar, H ^a   Ackerson, B ^a   Cheetham, T C ^a   Hansen, J ^a   Deosaransingh, K ^a   Emery, M ^a   Liaw, K L ^b   Jacobsen, S J ^a  

^a KAISER PERMANENTE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Autoimmune conditions; Human papillomavirus; Human papillomavirus vaccine; Postlicensure safety study; Vaccination; Vaccine safety

Indexed keywords

WART VIRUS VACCINE;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; CANCER IMMUNIZATION; CHILD; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; GRAVES DISEASE; GUILLAIN BARRE SYNDROME; HASHIMOTO DISEASE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; OBSERVATIONAL STUDY; ONSET AGE; OPTIC NEURITIS; PATIENT SAFETY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES; UVEITIS;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AUTOIMMUNE DISEASES; CALIFORNIA; CHILD; FEMALE; HUMANS; INCIDENCE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84855917730     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02467.x     Document Type: Article

References (14)

1. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-27.
2. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861-8.
3. Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-43.
4. Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-8.
5. Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18L1 virus-like particle vaccine through 5years of follow-up. Br J Cancer 2006; 95: 1459-66.
6. Stanley M, Lowy DR, Frazer I. Prophylactic vaccines: underlying mechanisms. Vaccine 2006; 24: S106-13.
7. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56: 1-24.
8. Randall DP. Guillain-Barre syndrome and immunizations. Dis Mon 2010; 56: 293-8.
9. Salemi S, D'Amelio R. Could autoimmunity be induced by vaccination? Int Rev Immunol 2010; 29: 247-69.
10. Chen RT, Pless R, Destefano F. Epidemiology of autoimmune reactions induced by vaccination. J Autoimmunol 2001; 16: 309-18.
11. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons, Inc., 1987.
12. Block SL, Brown DR, Chatterjee A et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J 2010; 29: 95-101.
13. Chen RT, Rastogi SC, Mullen JR et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 1994; 12: 542-50.
14. Slade BA, Leidel L, Vellozzi C et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302: 750-7.